Issue 11 2025 of the Malignant Haematology RESEARCH REVIEW™ is now out.
In it you can read about:
New Zealand multiple myeloma patients demonstrate inferior outcomes when compared to Australian counterparts. Authors: Li J et al.
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Authors: Mateos M-V et al.
Safety and efficacy of a dexamethasonesparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03). Authors: Manier S et al.
Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. Authors: Jagannath S et al.
